I6T-MC-AMBI
| abstract |
A Phase 3b, Randomized, Double-Blind, Parallel-Arm, Placebo- and
Active- Controlled Treat-Through Study of Mirikizumab and Vedolizumab in participants with Moderately to Severely Active Ulcerative Colitis |
| type of project | clinical studies |
| status | scheduled |
| start of project | 2021 |
| end of project | 2024 |
| responsible person | Prof. Dr. Stephan Brand |